Proposed Data Collection Submitted for Public Comment and Recommendations, 57435-57437 [2019-23366]
Download as PDF
<![CDATA[
57435
Federal Register / Vol. 84, No. 207 / Friday, October 25, 2019 / Notices
From 2007 to 2016, fall death ageadjusted rates increased by 31% with
almost 30,000 older adults dying as the
result of a fall in 2016. The economic
consequences of falls are significant and
growing as the population ages, with
medical costs of older adult falls
estimated at $50 billion. CDC created
the Stopping Elderly Accidents, Deaths,
and Injuries (STEADI) initiative to guide
health care providers’ fall prevention
activities in the primary care setting.
This new data collection effort is an
essential component to determine the
impact of CDC’s Stopping Elderly
Accidents, Deaths, and Injuries
(STEADI) initiative on falls, emergency
department visits, and hospitalizations
due to falls. It will help CDC determine
the impact of less resource intense
versions of STEADI and evaluate the
process of implementing STEADI fall
prevention initiative in a primary care
setting to provide context for the impact
evaluations. The study population will
be limited to adults 65 and older who
have an outpatient visit during the
study period and screen as high risk for
falls at the selected primary care clinics
implementing the STEADI fall
prevention initiative. The study
population for the process evaluation
will include the clinical implementation
staff at the selected clinics where the
intervention will take place (physicians,
physician assistants/nurse practitioners,
study research nurses, and practice or
operations manager).
Two data collection methods will be
used; the CDC’s Stay Independent Fall
Risk Screener will be administered to
older adult patients at selected primary
care clinics to determine which older
adults are at high risk for a fall. Those
who screen at high risk will be assigned,
based on clinic attended and week of
attendance, to one of three study arms.
Patient surveys will be used to
determine whether these patients
experience a fall during the study
period, are treated for a fall, and/or use
any fall prevention strategies throughout
the study period. Four surveys will be
administered to each patient during a
12-month period: One baseline survey
and three follow-up surveys. Older
adults will also be asked to keep track
of their falls in a monthly falls diary, so
they can accurately recall and report the
information during the 12-month period
for the patient surveys. The process
evaluation interviews will be used to
understand the attitudes of clinical staff
towards the implementation process,
barriers and facilitators to
implementation, and the
implementation fidelity to core
components of the STEADI initiative.
Descriptive statistics and cross
tabulations will be used to describe
quantitative data from the patient
survey and process evaluation data. Risk
ratios of the effect of the intervention on
post-intervention falls will be calculated
comparing intervention and control
groups while controlling for
demographic, health, attitude, and
behavior variables.
The data collected from this study
will be used to demonstrate the impact
of STEADI and different components of
STEADI on falls and fall injuries in a
primary care setting, and improve the
implementation of STEADI in a primary
care setting. There are no costs to the
respondents other than their time. The
total estimated annualized burden is
1,578 hours.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent
Number of
respondents
Average
burden per
response
(hours)
Type of respondent
Form name
Patient .............................................................
Stay Independent Fall Risk Screener (Att. D)
Consent Form (Att. C) ....................................
Patient Baseline Survey (Att. B1) ..................
Patient Follow-up Survey (Att. B2) ................
Provider Interview Guide/Consent (Att. E1) ...
4,035
1,235
1,000
896
3
1
1
1
3
1
6/60
12/60
15/60
15/60
50/60
Operations Manager Interview Guide/Consent (Att. E2).
2
1
50/60
Physician/Physician Assistants/Nurse Practitioners.
Clinic Operations Manager .............................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2019–23365 Filed 10–24–19; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–20–1158; Docket No. CDC–2019–
0095]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
AGENCY:
VerDate Sep<11>2014
18:04 Oct 24, 2019
Jkt 250001
ACTION:
Notice with comment period.
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on a
proposed information collection project
titled CDC Ideation Catalyst (I-Catalyst)
Program and Customer Engagement
Information Collection. CDC will collect
qualitative information from potential
customers and other stakeholders about
their needs and preferred approaches to
solving public health problems.
Findings will be used to improve
SUMMARY:
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
customer satisfaction with, and usability
of, CDC’s products, programs, and
services.
CDC must receive written
comments on or before December 24,
2019.
DATES:
You may submit comments,
identified by Docket No. CDC–2019–
0095 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS–D74, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
ADDRESSES:
E:\FR\FM\25OCN1.SGM
25OCN1
57436
Federal Register / Vol. 84, No. 207 / Friday, October 25, 2019 / Notices
change, all relevant comments to
Regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS–
D74, Atlanta, Georgia 30329; phone:
404–639–7570; Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected; and
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses.
5. Assess information collection costs.
Proposed Project
CDC Ideation Catalyst (I-Catalyst)
Program and Customer Engagement
Information Collection (OMB Control
No. 0920–1158, Exp. 1/31/2020)—
VerDate Sep<11>2014
18:04 Oct 24, 2019
Jkt 250001
Revision—Office of Science (OS),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
The CDC Office of Technology and
Innovation (OTI) within Office of
Science (OS) fosters innovative science
and promotes the testing and
implementation of innovative ideas that
improve CDC’s ability to have public
health impact. To arm CDC staff with an
expanded skill-set and tools to evaluate
and translate their insights and ideas
into solutions, CDC developed an
experiential innovation curriculum
called Ideation Catalyst (I-Catalyst). The
program was created with the belief that
innovation should be customer-driven,
be based on user research, and is
something people at all levels of an
organization can engage in. CDC also
obtained OMB approval for a generic
clearance to support the collection of
information from stakeholders and
customers, utilizing I-Catalyst program
principles and methodology (CDC ICatalyst Program, OMB Control No.
0920–1158, Exp. date 1/31/2020).
The goal of the I-Catalyst program is
to help CDC employees test and explore
their ideas through a discovery,
ideation, and prototyping process. ICatalyst offers a process for defining
problems and developing strategies to
solutions that will help improve the
quality and efficiency of innovation
efforts and, as a result, overall
performance. Through the I-Catalyst
Program, teams work to define and
articulate their problem space to find
effective solutions and CDC programs
receive consultation from OTI staff to
implement the I-Catalyst process with
specific projects. Participating teams
will go through a hypothesis-testing,
scientific method of discovery to gather
important insights and identify issues
associated with their projects. Teams are
forced ‘‘out of the classroom’’ to
conduct interviews, study customer/
stakeholder needs, collect feedback, and
find partnership opportunities. It is
expected that participants will gain the
ability to evaluate and translate their
insights into solutions.
The I-Catalyst process provides CDC
staff with real-world, hands-on
entrepreneurship training and
consultation from OTI staff. Through ICatalyst, CDC staff make hypotheses
about how the world works, and then
test them by getting out of the building
and talking to customers and/or
stakeholders. Only conversations with
potential customers/stakeholders can
provide the facts from which
hypotheses are proven or disproven
about whether a solution (whether a
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
product, process, etc.) creates value for
the intended beneficiaries. Participants
have to go out into the world and learn
by doing. I-Catalyst methods engage
customers/stakeholders in a process that
will identify what they most value and
need, and source solutions that will
have high levels of efficacy and user
acceptability.
The majority of data will be obtained
through on-site, unstructured interviews
with individuals who represent the
customers or stakeholders CDC teams
are attempting to serve or benefit. CDC
may also collect information through
telephone interviews, questionnaires, or
web-based surveys. With each CDC
program project, teams will interview
their customers/stakeholders with a
burden per response ranging from 20–60
minutes (an average of 30 minutes).
Each team will interview approximately
25 respondents. With 10–20 teams
participating annually and CDC program
consultations, approximately 500
respondents will be interviewed. Data to
be collected includes information
regarding needs, values, and barriers,
and facilitators to potential solutions.
CDC expects that teams participating
in the I-Catalyst process and OTI
consultations will be empowered to
implement innovative strategies and
solutions that create value for a set of
beneficiaries. The ultimate goal is to
give CDC staff skills to successfully
transfer knowledge into value-based
solutions that benefit society and
broaden the agency’s impact.
In this Revision request, CDC seeks
approval for minor changes to the ICatalyst generic clearance. The number
of burden hours will decrease based on
participation in the I-Catalyst training
program during the period 2017–2019.
However, through related technical
assistance provided by OTI to CDC/
ATSDR programs, CDC has identified
additional opportunities for information
collection compatible with I-Catalyst
goals and methods. During the next
three-year period CDC anticipates
utilization of the I-Catalyst generic
clearance by previous participants in
the I-Catalyst training program, as well
as other CDC programs implementing
customer discovery projects. The title of
the clearance is being updated to reflect
its use by additional CDC/ATSDR
project teams approved by OTI. The ICatalyst clearance will continue to be
used for information collections
necessary to explore the needs and
preferences of specific stakeholder
groups, and to facilitate and improve the
acceptance and usability of CDC
products, programs, and technologies.
All projects submitted to OMB for
approval under the I-Catalyst generic
E:\FR\FM\25OCN1.SGM
25OCN1
57437
Federal Register / Vol. 84, No. 207 / Friday, October 25, 2019 / Notices
clearance will be consistent with CDC/
OTI goals for promoting scientific
innovation, customer engagement, and
entrepreneurship in public health.
OMB approval is requested for three
years. Individual projects must be
approved by CDC’s OTI before they are
submitted to OMB for final review and
approval. CDC estimates the estimated
annual burden hours to be 250.
Participation is voluntary, and there are
no costs to respondents other than their
time.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Number of
responses per
respondent
Avg. burden
per response
(in hrs.)
Total burden
(in hrs.)
Type of respondents
Form name
External Partners, Stakeholders, or
Customers.
Interview Guides, Questionnaires,
and Surveys.
500
1
30/60
250
Total ...........................................
...........................................................
........................
........................
........................
250
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2019–23366 Filed 10–24–19; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–20–1128]
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘State
Unintentional Drug Overdose Reporting
System (SUDORS)’’ to the Office of
Management and Budget (OMB) for
review and approval. CDC previously
published a ‘‘Proposed Data Collection
Submitted for Public Comment and
Recommendations’’ notice on April 2,
2019 to obtain comments from the
public and affected agencies. CDC did
not receive comments related to the
previous notice. This notice serves to
allow an additional 30 days for public
and affected agency comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
VerDate Sep<11>2014
18:04 Oct 24, 2019
Jkt 250001
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Direct
written comments and/or suggestions
regarding the items contained in this
notice to the Attention: CDC Desk
Officer, Office of Management and
Budget, 725 17th Street NW,
Washington, DC 20503 or by fax to (202)
395–5806. Provide written comments
within 30 days of notice publication.
Proposed Project
State Unintentional Drug Overdose
Reporting System (SUDORS) (OMB
Control No. 0920–1128, Exp. 10/31/
2020)—Revision—National Center for
Injury Prevention and Control (NCIPC),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
There has been a rapid increase in
opioid overdose deaths since 2013. In
the United States, more people are now
dying of drug overdose than automobile
crashes, although opioids—both opioid
pain relievers (OPRs) and illicit forms
such as heroin—are also a major factor
in overdose-related automobile crashes.
On October 26, 2017, the U.S.
Department of Health and Human
Services (HHS) declared the opioid
overdose epidemic to be a national
public health emergency.
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
CDC established the State
Unintentional Drug Overdose Reporting
System (SUDORS) in order to detect
new trends in fatal unintentional drug
overdoses, support targeting of drug
overdose prevention efforts, and assess
the progress of the HHS initiative to
reduce opioid misuse and overdoses.
Respondents are state- or jurisdictionlevel health departments. The SUDORS
surveillance system generates detailed,
timely public health information on
unintentional, fatal opioid-related drug
overdoses and has been used to inform
prevention and response efforts at the
national, state, and local levels.
SUDORS consolidates and supplements
information available to health
departments, including vital statistics
and records created by medical
examiners and coroners (ME/C).
SUDORS is built on a web-based
software platform and a collaborative
surveillance and data integration model
developed by CDC and health
departments to improve understanding
of homicide, suicide, undetermined
deaths, and unintentional firearm
deaths (National Violent Death
Reporting System (NVDRS), OMB No.
0920–0607, exp. 11/30/2020).
Through SUDORS, CDC currently
collects information that is not provided
on death certificates, such as whether
the drug(s) causing the overdoses were
injected or taken orally; a toxicology
report on the decedent, if available; and
risk factors for fatal drug overdoses
including previous drug overdoses,
decedent’s mental health, and whether
the decedent recently exited a treatment
program. Without this information,
efforts to prevent drug overdose deaths
are often based on limited information
available on the death certificate and
anecdotal evidence.
During the next three years, CDC will
update the web-based SUDORS
interface to improve system
performance, functionality, and
accessibility. CDC and health
E:\FR\FM\25OCN1.SGM
25OCN1
]]>Agencies
[Federal Register Volume 84, Number 207 (Friday, October 25, 2019)]
[Notices]
[Pages 57435-57437]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-23366]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-20-1158; Docket No. CDC-2019-0095]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
Federal agencies the opportunity to comment on a proposed and/or
continuing information collection, as required by the Paperwork
Reduction Act of 1995. This notice invites comment on a proposed
information collection project titled CDC Ideation Catalyst (I-
Catalyst) Program and Customer Engagement Information Collection. CDC
will collect qualitative information from potential customers and other
stakeholders about their needs and preferred approaches to solving
public health problems. Findings will be used to improve customer
satisfaction with, and usability of, CDC's products, programs, and
services.
DATES: CDC must receive written comments on or before December 24,
2019.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2019-
0095 by any of the following methods:
Federal eRulemaking Portal: Regulations.gov. Follow the
instructions for submitting comments.
Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS-D74, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without
[[Page 57436]]
change, all relevant comments to Regulations.gov.
Please note: Submit all comments through the Federal eRulemaking
portal (regulations.gov) or by U.S. mail to the address listed above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Jeffrey M. Zirger, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road NE, MS-D74, Atlanta, Georgia 30329; phone: 404-639-7570; Email:
[email protected].
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
Federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected; and
4. Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submissions of responses.
5. Assess information collection costs.
Proposed Project
CDC Ideation Catalyst (I-Catalyst) Program and Customer Engagement
Information Collection (OMB Control No. 0920-1158, Exp. 1/31/2020)--
Revision--Office of Science (OS), Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
The CDC Office of Technology and Innovation (OTI) within Office of
Science (OS) fosters innovative science and promotes the testing and
implementation of innovative ideas that improve CDC's ability to have
public health impact. To arm CDC staff with an expanded skill-set and
tools to evaluate and translate their insights and ideas into
solutions, CDC developed an experiential innovation curriculum called
Ideation Catalyst (I-Catalyst). The program was created with the belief
that innovation should be customer-driven, be based on user research,
and is something people at all levels of an organization can engage in.
CDC also obtained OMB approval for a generic clearance to support the
collection of information from stakeholders and customers, utilizing I-
Catalyst program principles and methodology (CDC I-Catalyst Program,
OMB Control No. 0920-1158, Exp. date 1/31/2020).
The goal of the I-Catalyst program is to help CDC employees test
and explore their ideas through a discovery, ideation, and prototyping
process. I-Catalyst offers a process for defining problems and
developing strategies to solutions that will help improve the quality
and efficiency of innovation efforts and, as a result, overall
performance. Through the I-Catalyst Program, teams work to define and
articulate their problem space to find effective solutions and CDC
programs receive consultation from OTI staff to implement the I-
Catalyst process with specific projects. Participating teams will go
through a hypothesis-testing, scientific method of discovery to gather
important insights and identify issues associated with their projects.
Teams are forced ``out of the classroom'' to conduct interviews, study
customer/stakeholder needs, collect feedback, and find partnership
opportunities. It is expected that participants will gain the ability
to evaluate and translate their insights into solutions.
The I-Catalyst process provides CDC staff with real-world, hands-on
entrepreneurship training and consultation from OTI staff. Through I-
Catalyst, CDC staff make hypotheses about how the world works, and then
test them by getting out of the building and talking to customers and/
or stakeholders. Only conversations with potential customers/
stakeholders can provide the facts from which hypotheses are proven or
disproven about whether a solution (whether a product, process, etc.)
creates value for the intended beneficiaries. Participants have to go
out into the world and learn by doing. I-Catalyst methods engage
customers/stakeholders in a process that will identify what they most
value and need, and source solutions that will have high levels of
efficacy and user acceptability.
The majority of data will be obtained through on-site, unstructured
interviews with individuals who represent the customers or stakeholders
CDC teams are attempting to serve or benefit. CDC may also collect
information through telephone interviews, questionnaires, or web-based
surveys. With each CDC program project, teams will interview their
customers/stakeholders with a burden per response ranging from 20-60
minutes (an average of 30 minutes). Each team will interview
approximately 25 respondents. With 10-20 teams participating annually
and CDC program consultations, approximately 500 respondents will be
interviewed. Data to be collected includes information regarding needs,
values, and barriers, and facilitators to potential solutions.
CDC expects that teams participating in the I-Catalyst process and
OTI consultations will be empowered to implement innovative strategies
and solutions that create value for a set of beneficiaries. The
ultimate goal is to give CDC staff skills to successfully transfer
knowledge into value-based solutions that benefit society and broaden
the agency's impact.
In this Revision request, CDC seeks approval for minor changes to
the I-Catalyst generic clearance. The number of burden hours will
decrease based on participation in the I-Catalyst training program
during the period 2017-2019. However, through related technical
assistance provided by OTI to CDC/ATSDR programs, CDC has identified
additional opportunities for information collection compatible with I-
Catalyst goals and methods. During the next three-year period CDC
anticipates utilization of the I-Catalyst generic clearance by previous
participants in the I-Catalyst training program, as well as other CDC
programs implementing customer discovery projects. The title of the
clearance is being updated to reflect its use by additional CDC/ATSDR
project teams approved by OTI. The I-Catalyst clearance will continue
to be used for information collections necessary to explore the needs
and preferences of specific stakeholder groups, and to facilitate and
improve the acceptance and usability of CDC products, programs, and
technologies. All projects submitted to OMB for approval under the I-
Catalyst generic
[[Page 57437]]
clearance will be consistent with CDC/OTI goals for promoting
scientific innovation, customer engagement, and entrepreneurship in
public health.
OMB approval is requested for three years. Individual projects must
be approved by CDC's OTI before they are submitted to OMB for final
review and approval. CDC estimates the estimated annual burden hours to
be 250. Participation is voluntary, and there are no costs to
respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Avg. burden
Type of respondents Form name Number of responses per per response Total burden
respondents respondent (in hrs.) (in hrs.)
----------------------------------------------------------------------------------------------------------------
External Partners, Interview 500 1 30/60 250
Stakeholders, or Customers. Guides,
Questionnaires,
and Surveys.
---------------------------------------------------------------
Total..................... ................ .............. .............. .............. 250
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2019-23366 Filed 10-24-19; 8:45 am]
BILLING CODE 4163-18-P
